Introduction
Pharmaceutical compounds obtained with new synthesis procedures have tended towards higher molecular weights and lipophilicity, which allows drugs to cross membranes more easily. However, molecular properties that promote permeation often decrease solubility, and then bioavailability is diminished. In addition, some poorly water-soluble molecules are also not very lipophilic (Box and Comer, 2008) . To understand the relationship between solubility and permeability, and visualize its potential impact on drug absorption, the Biopharmaceutics Classification Scheme (BCS) is used (FDA Guidance, 2015) . This scheme classifies all molecules in 4 different classes on the basis of solubility and permeability. Molecules in class I are considered to be highly soluble and highly permeable, very suitable for pharmaceutical purposes.
Molecules in class II have limited solubility but are permeable, while molecules in Class III are soluble but poorly permeable. Finally, molecules in Class IV have low solubility and low permeability (Box and Comer, 2008; Tsume et al., 2014) .
In order to achieve desirable drug absorption, active molecules should be soluble to a given extent in aqueous media to ensure they are dissolved in biological fluids once inside the human body (Takács-Novák et al., 2013) . Therefore, aqueous solubility is, among others, an essential property to assess during early stages of drug development (Shoghi et al., 2013) . Several methods can be used to increase drug solubility, especially for class II compounds which often exhibit solubility-limited absorption. Some of them are focused on solubilizing formulations (i.e. enhancing the solubilizing capacity in the gastrointestinal environment), and other methods are focused on maintaining the drug in a supersaturated state, so it can be available at higher concentrations than its equilibrium solubility for a certain period of time (Williams et al., 2013; Brouwers et al., 2009 ). However, it must be considered that solubility increase in biological fluids may only need to be fleeting, so the maintenance of a temporary state of supersaturation would be enough to make the drug available for permeation (Warren et al., 2010) . In other words, keeping the concentration of the drug higher than its equilibrium intrinsic solubility only during the digestion time may be sufficient to promote absorption.
For pure drugs, kinetic solubility S k (or concentration when first precipitation occurs) is generally higher than the intrinsic solubility S 0 , indicating that the drug solution is frequently supersaturated just before precipitate is first observed (Box and Comer, 2008; Shoghi et al., 2009 ). However, a supersaturated drug solution is thermodynamically unstable and has the tendency to return to the equilibrium state by precipitation to the crystalline most stable form of the drug. This process can be slowed down or inhibited using some solubility enhancement strategies ( (Williams et al., 2013; Brouwers et al., 2009; Xu and Dai, 2013; Ilevbare et al., 2013) . Among other approaches, the use of different pharmaceutical excipients like polymers, surfactants or cyclodextrins as stabilizers of supersaturation is common practice. In these cases, the stabilizer effect does depend not only on the type of stabilizer, but also on the excipient:drug ratio, and the initial degree of supersaturation of the drug (Brouwers et al., 2009; Ilevbare et al., 2013; Khougaz and Clas, 2000; Chauhan et al., 2013) .
Poly(vinylpyrrolidone) (PVP) polymers have been extensively studied regarding their ability to modify drugs' solubility. Some works are centered on the impact of PVP on the inhibition of crystallization of drugs (Khougaz and Clas, 2000; Chauhan et al., 2013; Ozaki et al., 2013) ; other works are focused on the knowledge of the specific interactions between drugs and PVP (Khougaz and Clas, 2000; Karavas et al., 2006; Karavas et al., 2007; Tajber et al., 2005; Nair et al., 2001; Molyneux and Frank, 1961a; Molyneux and Frank, 1961b) which, according to FTIR experiments, seems to be related to the ability of PVP units to form hydrogen bonds either through the nitrogen or the carbonyl group on the pyrrole ring. Most of these studies employ only one particular type of PVP (i.e. with a particular degree of polymerization, which ranges from 12 to 90 in the above mentioned studies) and a few different drugs. In the present work, a systematic study taking into account the degree of polymerization of the PVP and the PVP:drug ratio is addressed. In particular, the effect of these two parameters on the degree and extent of supersaturation of different BCS class II drugs is evaluated.
Materials and methods

Instruments
All solubility assays were carried out by the CheqSol method (Stuart and Box, 2005 ) using a PCA200 titrator from Sirius Analytical Instruments Ltd. (Forest Row, UK), equipped with a Sirius D-PAS spectrometer, a bifurcated fibre-optic dip probe from Hellma Analytics (Müllheim, Germany) with path length of 1 cm, and a two channels solvent degasser from SMI-LabHut Ltd. (Churcham, UK). The apparatus was controlled from a computer running the RefinementPro2 and Cheqsol software. Acidity constant determinations were performed using either the PCA220 or a GLpK a titrator also from Sirius Analytical Instruments Ltd.
The X-ray diffraction (XRD) characterization was performed using a PANalytical X'Pert PRO MPD θ/θ powder diffractometer of 240 mm of radius equipped with a PIXcel detector from PANalytical B.V. (Almelo, The Netherlands). The apparatus was set in a configuration of convergent beam with a focalizing mirror and a transmission geometry, with flat samples sandwiched between low absorbing films. The detector active length was 3.347°. Work power was 45 kV-40 mA with a defined beam height of 0.4 mm. Five repeated scans were performed from 2 to 60 2θ°with a step size of 0.026 2θ°and a measuring time of 40 s per step.
Reagents
Dimethyl sulfoxide > 99.9% (DMSO), 0.5 M potassium hydroxide tritisol and 0.5 M hydrochloric acid tritisol were purchased from Merck (Darmstadt, Germany). Potassium chloride > 99% was from Sigma (St. Louis, MO, USA), and potassium hydrogen phthalate > 99% was from Probus (Strassen, Luxembourg). PVP K-12, K-17, K-25, K-29/32, K-90 and S-630 were from International Specialty Products (Wayne, NJ, USA), and provided by Ashland (Covington, KY, USA). K-type PVP are homopolymers of polyvinylpyrrolidone that differ in molecular weight (MW) and glass transition temperature (T g ); K represents degree of polymerization, thus the higher K the higher MW and T g . PVP S-630 is a 60:40 random copolymer of vinylpyrrolidone and vinylacetate; it has a lower T g and is less hygroscopic than K-type PVP (Ashland Inc., 2013 All measurements were performed at least in triplicate, under argon atmosphere, at 25 ± 0.1°C, using standardized 0.5 M HCl and 0.5 M KOH solutions as titrants. The pH electrode (Ag/AgCl, Sirius Analytical Instruments Ltd.) was calibrated titrimetrically in the pH range 1.8-12.2. Temperature was monitored through a temperature probe during the course of the measurement.
Spectrophotometric titration was the method of choice to determine acidity constants of the test compounds. pK a values were determined from pH-dependent multi-wavelength UV spectra collected by the D-PAS system. In each experiment, 50 μL of a drug stock solution (10 mM in DMSO) were introduced in 10 mL of a 0.15 M KCl ionic strength adjusted (ISA) aqueous solution, and titrated between pH 2 and pH 12.
The pK a of haloperidol and the second pK a of dibucaine, whose ionisable groups showed not enough UV activity (Allen et al., 1998) , were determined through a conventional potentiometric titration (Albert and Serjeant, 1984) 
Solubility determination
Solubility measurements were carried out using the CheqSol method, which is described in detail elsewhere (Stuart and Box, 2005) . Briefly, 10 mL of ISA solution are added to an accurately weighted amount of drug. The pH is immediately adjusted to a value where the compound exists predominantly in its ionized form, titration starts (by addition of amounts of KOH or HCl, according to the nature of the compound), and solubility is reduced by increasing the concentration of the neutral species. When a certain extent of supersaturation is achieved, precipitation starts. At this point, small amounts of acidic and basic titrant are alternately added, creating subsequent positive and negative pH gradients, which in turn make the drug solution go alternately from subsaturated to supersaturated. The solubility of the neutral species (S 0 ) is determined from the point at which the pH gradient becomes zero, i.e. where no net dissolution or precipitation of the compound occurs, through mass and charge balances and the pK a of the compound. All measurements were performed at least in triplicate.
The weight of sample needed to perform the assay depends on the compound's intrinsic solubility and may vary between 5.00 and 20.00 mg. The temperature was set to 25 ± 0.5°C and an argon atmosphere was used to avoid the presence of carbon dioxide in solution and its influence on the titration data. When carrying out the solubility assays in the presence of PVP, a physical mixture of the drug and the PVP was used. The percentage of PVP in the assay was calculated as follows:
Supersaturation determination
Extent and time in which a solution stays supersaturated are the parameters used to evaluate supersaturation. Determinations performed through the CheqSol method provide this information since the drug concentration is monitored over time. Henceforth, dividing the maximum measured concentration of neutral species (C max ) by the intrinsic solubility (S 0 ), the supersaturation ratio (R ss ) can be calculated.
Also the duration of the supersaturation state (t ss ) can be measured from the concentration vs. time data by calculating the time lapse Δt in which supersaturation occurs (Hsieh et al., 2012) .
X-ray diffraction characterization
In order to characterize the precipitate obtained while the solution is supersaturated, the solubility assay was aborted at the desired time point. Then, the solid was filtered through a 0.45 μm filter paper, and the filters were then left in a vacuum dessicator for one day. The solid material was carefully collected and prepared for XRD characterization.
Results and discussion
Physicochemical properties of studied compounds
Structures of the tested compounds are shown in Table 1 . They are of different chemical nature, and include 2 diprotic acids (bendroflumethiazide and benzthiazide) which belong to the same family, 4 monoprotic acids (diclofenac, isoxicam, ketoprofen, and warfarin), 3 diprotic bases (dibucaine, olanzapine and tetracaine), and 7 monoprotic bases (bupivacaine, cyproheptadine, haloperidol, maprotiline, papaverine, pindolol, and propranolol). pK a and S 0 of the compounds have been determined and results are also shown in Table 1 . Bupivacaine is the most soluble of the drugs with log S 0 = −2.93 ± 0.05, whereas isoxicam is the least soluble with log S 0 = −5.61 ± 0.14. It is normal behavior that compounds show a certain degree of supersaturation just before precipitation occurs (Hsieh et al., 2012) . For this reason, it is important to know the extent of the supersaturation of the compound itself, so that the effect of the addition of PVP can be correctly interpreted. The maximum concentration of neutral species (C max ), and supersaturation ratio (R ss ) and time (t ss ) of the drugs are also provided in Table 1 . As an example, Fig. 1 shows the concentration profile of bendroflumethiazide during a typical Cheqsol experiment. In this exemplary experiment C max is around 1500 μM, whereas S 0 is 80 μM, which provides a R ss around 18, i.e. the concentration of bendroflumethiazide is 18 times higher than its equilibrium solubility just before precipitation starts. In this example the duration of the supersaturation state, t ss , is about 12 min. Values provided in Table 1 are the average of several replicate measurements. It can be observed that C max and t sat often have high standard deviations. This is not unusual because as supersaturation is a non-equilibrium process, it can be easily affected by many environmental factors, which lead to high dispersion in the obtained values even in replicate measurements. According to the obtained results, papaverine and isoxicam are the compounds that supersaturate most highly, compared to the intrinsic solubility, reaching concentrations almost sixty-fold greater than S 0 . On the contrary, bupivacaine and tetracaine hardly supersaturate, since the ratio C max /S 0 is close to 1. With regards to supersaturation time, the longest supersaturation times following precipitation are around 15-20 min, whereas the shortest ones are in the range 4-5 min.
Effect of PVP on the solubility of the drugs
To check the effect of PVP on drugs solubility, Cheqsol experiments were repeated using physical mixtures of drug-PVP. The effect of all available PVP at different PVP:drug proportions was tested. Three different trends were observed for the selected compounds related to their supersaturation, and three model compounds have been selected to explain each one of the behaviors: bendroflumethiazide (case A), benzthiazide (case B), and tetracaine (case C).
Case A: long-time stabilization of the supersaturated state
This is the case of bendroflumethiazide, diclofenac, ketoprofen, and warfarin. Fig. 2A shows how the concentration of bendroflumethiazide changes with time when different proportions of PVP K-12 are present in the mixture. In the absence of PVP, after reaching C max , concentration decreases until the S 0 value is reached. However, when PVP are present, solutions stay supersaturated at nearly the C max concentration of the drug for the whole duration of the experiment. So, in this case PVP do not increase the maximum concentration of drug in solution, but keep this concentration stable for a long time, improving the potential bioavailability. As regards the effect of the PVP:drug ratio, there is a slight decrease of supersaturation concentration when the percentage of PVP increases. Nevertheless, all solutions keep supersaturated at all ratios PVP:drug, with degrees ranging from 7.6 (70%) to 15 (10%) for > 2 h. It is worth noting that the reproducibility between replicate measurements is more variable at low PVP:drug ratios (Fig. 2B) . Best reproducibility is obtained in the range 40-70% PVP.
The effect of the PVP polymerization degree has also been tested. Fig. 3 shows the results of solubility measurements for bendroflumethiazide when different PVP (all of them in a 50% PVP:drug ratio) are used. Apparently there is no effect of the degree of polymerization on the supersaturation of the drug, since all K-type PVP provide the same results. Previous studies based on FTIR measurements had already pointed out existing interactions between bendroflumethiazide and Ktype PVP (Tajber et al., 2005; Frontini and Mielck, 1997) , mainly through hydrogen bonding interactions of the sulfonamide groups of bendroflumethiazide and the vinylpyrrolidone units. However, PVP S-630, which contains vinylacetate moieties randomly distributed in addition to the vinylpyrrolidone ones, hardly modifies solubility behavior of bendroflumethiazide. This latter polymer was tested at different PVP:drug ratios obtaining similar results (Table S1 of the Supporting material) at all S-630 levels. 
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Diclofenac, ketoprofen and warfarin behave as bendroflumethiazide in the presence of PVP. Results for these three other compounds are shown in Fig. 4 . Diclofenac (Fig. 4A) and ketoprofen (Fig. 4B) interact only with K-type PVP, and solubility of the compounds is stabilized at 17-fold and 2-fold its intrinsic solubility value, respectively. Warfarin (Fig. 4C) shows positive interaction not only with K-type PVP, but also with PVP S-630. All types of PVP make the solubility of warfarin increase approximately 20 times.
Case B: Increase of the supersaturation concentration for a limited time
In this other case, the effect of PVP on drug's solubility is completely different. Now, the addition of PVP makes C max of the drugs increase, but for a limited period of time. Thus, the drug could be potentially more bioavailable, but because of the higher concentration in the supersaturated solution. This is the case of benzthiazide, isoxicam, olanzapine, and pindolol. Focusing on benzthiazide as a model compound, the addition of K-type PVP makes C max increase from around 100 μM to about 1000 μM, depending on the added PVP and its percentage (Table 
Neutral species concentraƟon (μM)
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S2 of the Supporting material). In the same way, supersaturation time increases from 4 min (benzthiazide alone) to a range between 15 and 45 min, depending on the PVP and percentage added. There is not a clear trend that relates R ss with the polymerization degree or the percentage of PVP. However, it seems that higher percentages of PVP enlarge the supersaturation time of the drug. The addition of PVP S-630 provokes a greater effect than K-type PVP on benzthiazide solubility (Fig. 5A ). R ss is increased from 8 to 44 when the percentage of S-630 is 10%, to 109 when it is 50%, and to 720 at 75% of PVP. In the same way, supersaturation time increases from 4 min to around 25, 30, and 40 min at 10%, 50%, and 75% S-630 respectively. Although the general effect on solubility is the same for all mentioned compounds (an increase in the supersaturation concentration for a given period of time), the results obtained for each individual compound may change according the type of PVP and its percentage. For example, pindolol has a similar increase in supersaturation ratio (from 15 to 50-60) and time (from 6 to 20-30 min) independently of the percentage and type of PVP used (Fig. 5B) . However olanzapine shows a moderate increase in supersaturation degree depending on the used PVP, and also an important modification in the supersaturation time; it changes from nearly 6 min to 25 min with a 65% S-630 addition (Fig. 5C ). Similar behavior is observed for isoxicam (Fig. 5D ), which shows a R ss around two times the level of the compound alone, and a t ss 3 or 4-fold higher. The results obtained as regards C max , R ss and t ss for the aforementioned compounds are summarized in Table S2 of the Supplementary information.
Case C: no effect on the solubility of the drugs
In the third case there is no interaction at all between the drug and the different PVP, so that solubility is not affected by the addition of the polymers. This happens to bupivacaine, cyproheptadine, dibucaine, haloperidol, maprotiline, papaverine, propranolol, and tetracaine. Fig. 6 shows the supersaturation profile of tetracaine in absence and presence of 50% of K-type and S-630 PVP. In all instances the profile is identical, and practically the same results are obtained at other percentages (Table S3 of the Supplementary information). Although small increases in t s are observed in some instances, they can be attributed to the kinetic factors which can delay or accelerate the precipitation of a compound.
Effect of PVP on the morphology of the precipitates
X-ray diffraction (XRD) assays were performed for the two model compounds that presented a clear modification of solubility behavior in presence of PVP, i.e. bendroflumethiazide and benzthiazide. This analysis was performed with the PVP that caused stronger modifications to the solubility of the mentioned compounds, so K-12 was chosen for bendroflumethiazide and S-630 for benzthiazide. The aim was to assess if observed changes in drugs solubility behaviors were due to modifications in solid forms when precipitation occurred, induced by the Bendroflumethiazide spectra belongs to an amorphous solid (Fig. 7A,d ). Only two sharp peaks are present, which belong to the KCl present in the titration measurements. In this case PVP induces the precipitation of a metastable amorphous form, with higher solubility than the crystalline one (Hsieh et al., 2012) . Instead, the spectra obtained for benzthiazide (Fig. 7B,d ) belongs to a crystalline solid, and can be considered equivalent to the one obtained in absence of PVP. In this case the presence of PVP may inhibit precipitation, and higher concentrations of drug can be reached in solution. However, after a relative short time the polymorph of benzthiazide starts to precipitate in the same form obtained in absence of PVP, so concentration in solution falls to the S 0 value. According to the observed results it is difficult to predict a clear effect of PVP on a given drug. However, it must be pointed out that all the acidic compounds of the present work modify its solubility behavior in presence of PVP; on the other hand, solubility of basic compounds is hardly affected by PVP, although some bases like olanzapine and pindolol improved temporarily their supersaturation degree and duration by the addition of PVP. Molyneux et al. (Molyneux and Frank, 1961a; Molyneux and Frank, 1961b) already indicated that anionic aromatic compounds interact with PVP polymers. They demonstrated that the binding constants anion-PVP increased as the volume of the anionic compound increased (possibly due to coulombic repulsions between the anions bound to the polymer coil). In the same studies, they reported that basic compounds did not interact with PVP. However, other studies have shown interactions between some basic compounds and PVP, especially with compounds containing heterocyclic nitrogen atoms in highly conjugated rings (Karavas et al., 2007) or sulphonamide groups (Tajber et al., 2005) . In these cases a hydrogen bond can form between the -N-H moiety of the drug and the oxygen of the pyrrole group of PVP. That might be the case of olanzapine and pindolol, which contain heterocyclic nitrogen atoms in highly conjugated structures. 
Conclusions
The used methodology provides an excellent way to study the supersaturation state of drug formulations, since the constant measurement of drug concentration in solution allows the determination of supersaturation extent and duration. The results from the present study demonstrate that the use of PVP polymers in the formulation of certain drugs can potentially improve their bioavailability by increasing the concentration of the drug in solution for a given period of time. In general, solubility of acidic compounds is clearly affected by PVP, although two different behaviors have been observed with such kind of compounds: in the first case PVP maintain a supersaturated system for a long period of time by the stabilization of the amorphous form of the compounds, as evidenced by the solid state characterization; in the second case PVP maintain the solution supersaturated in a higher degree compared to the compound alone, but only for a limited period of time. Then a crystalline form of the drug precipitates, and solubility drops to the equilibrium solubility value of the drug.
The type of PVP and the PVP:drug ratio play a role in the supersaturation of the drugs, but there is not a clear relation between the obtained effect and the type and ratio of PVP, since different effects have been observed in different drugs.
From the ten basic compounds studied in the present work, only two showed modified solubility behavior by the addition of PVP. This fact points out that the effect of PVP on solubility of basic drugs is not so evident, being the modification of solubility behavior by PVP highly drug-structure dependent.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.ejps.2018.02.025. 
